Arbutus Biopharma Corp Intangible Assets, Net (Excluding Goodwill)
Arbutus Biopharma Corp (ABUS) had Intangible Assets, Net (Excluding Goodwill) of $0 as of 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2020-03-05
- 2019-12-31: Intangible Assets, Net (Excluding Goodwill) $0.00.
- 2019-09-30: Intangible Assets, Net (Excluding Goodwill) $0.00.
- 2019-06-30: Intangible Assets, Net (Excluding Goodwill) $43.84M.
- 2019-03-31: Intangible Assets, Net (Excluding Goodwill) $43.84M.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-05 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-06 |
| 2019-06-30 | $43.84M 10-Q · filed 2019-08-05 |
| 2019-03-31 | $43.84M 10-Q · filed 2019-05-06 |
| 2018-12-31 | $43.84M 10-K · filed 2020-03-05 |
| 2018-09-30 | $43.84M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $58.65M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $58.65M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $58.65M 10-K · filed 2019-03-07 |
| 2017-09-30 | $99.44M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $99.44M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $99.44M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $99.44M 10-K · filed 2018-03-16 |
| 2016-09-30 | $196.32M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $196.32M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $352.64M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $352.64M 10-K · filed 2017-03-22 |
| 2015-09-30 | $353.60M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $390.02M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $389.65M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |